EXHIBIT 99.01
| Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com |  |
Press Release
FOR IMMEDIATE RELEASE
22 June 2005
Shire Pharmaceuticals Group plc AGM – 2005
Results of the Annual General Meeting
Shire Pharmaceuticals Group plc held its Annual General Meeting today. All resolutions were put to the meeting and approved on a show of hands. The proxy votes received for the meeting are set out below:
| For | Against | Abstention | ||
| 1. | To receive and consider the directors’ report and accounts for the year ended 31 December 2004 | 390,982,100 | 652,340 | 3,146,277 |
| 2. | To re-elect Mr Matthew William Emmens as a director | 389,563,578 | 3,279,709 | 1,937,430 |
| 3. | To re-elect Mr Ronald Maurice Nordmann as a director | 387,779,176 | 3,082,640 | 3,918,901 |
| 4. | To re-elect Dr Barry John Price as a director | 386,034,142 | 3,946,865 | 4,799,710 |
| 5. | To re-appoint Deloitte & Touch LLP as Auditors | 387,710,401 | 4,642,337 | 2,427,979 |
| 6. | To authorise the Audit Committee to determine the remuneration of the Auditors | 392,716,407 | 1,103,374 | 960,936 |
| 7. | To approve the Directors’ Remuneration Report | 379,661,987 | 6,796,998 | 8,321,732 |
| 8. | To authorise the allotment of shares | 390,798,549 | 2,930,801 | 1,051,367 |
| 9. | To authorise the disapplication of pre-emption rights | 390,522,104 | 3,182,677 | 1,075,936 |
| 10. | To authorise market purchases | 393,533,510 | 172,481 | 1,074,726 |
| 11. | To authorise donations to EU political organisations and EU political expenditure | 384,375,349 | 7,229,220 | 3,176,148 |
Registered in England 2883758 Registered Office as above
For further information please contact:
| Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
| Brian Piper (North America) | +1 484 595 8252 |
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com.
“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization, the impact of competitive products, including, but not limited to, the impact of those on Shire’s ADHD franchise, patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise, government regulation and approval, including but not limited to Health Canada’s suspension of ADDERALL XR® sales in Canada and the expected product approval dates of MTS (METHYPATCH) (ADHD), SPD503 (ADHD), SPD465 (ADHD), SPD476 (ulcerative colitis), SPD480 (ulcerative colitis) and NRP104 (ADHD), including its scheduling classification by the Drug Enforcement Agency in the United States, Shire’s ability to consummate and benefit from its proposed acquisition of TKT, Shire’s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year to December 31, 2004.